Brazil has decided to temporarily suspend the world's first-ever dengue vaccine after two deaths. The jab, Butantan-DV, was stalled by Brazil's Ministry of Health on Monday. The authorities have reported that the decision came as a preventive step; it does not conclude that the deaths were connected with the shot.The ministry has also given information that about 500 thousand doses of vaccine already administered by 30th May 2026, and among them 3,703 reports of adverse effects, thus it is roughly 0.7% of those vaccinated. Among these 42 cases, one was severe dengue and caused abdominal pain, persistent vomiting, and bleeding; thus, this group represents about 0.008% of the total immunized.The National Pharmacovigilance Committee recommended this suspension. Analyzing the situation and studying reports made by municipal, state, and federal surveillance systems. According to the Minister of Health, Alexandre Padilha, three cases were classified as severe. Of this total, two resulted in death. As per the reports, the Butantan Institute is going to convene a committee of experts for epidemiological investigation. The institute will be responsible for sharing data with the health authorities. According to Butantan, the vaccine has a global efficacy of 79.6% and 89% protection against severe dengue in a study published in the scientific journal Nature.The Butantan-DV VaccineThe Butantan-DV vaccine is tetravalent and offers protection against the four known serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.The vaccine uses live viruses that have been “weakened” (attenuated) in a laboratory.Once administered, the vaccine controls replication of these attenuated viruses in the body -- a process which induces the immune system to produce neutralizing antibodies specific to each of the four serotypes.The vaccines create immunity specific to each serotype to enable the body to recognize and neutralize each variant individually.The Butantan-DV vaccine was approved by the Brazilian Health Regulatory Agency (ANVISA) on November 26, 2025, for use by the Brazilian population aged 12 to 59.The country's Ministry of Health has incorporated the vaccine into the national immunization program in Januarylaunched a pilot project to immunize 90 percent of the target population in states with a high burdenrolled out vaccination of primary care health professionals in February.Also Read: Salmonella Outbreak: Instant Noodles Sicken Over 80 In The UK, EuropeWhat Is Dengue?Dengue is a viral infection that is primarily transmitted to the human body through mosquito bites. About 100 to 400 million people across the globe get infected with this disease every year. Usually, this condition is asymptomatic in its initial stages and leads to mild illness. However, occasionally, the virus can develop severe dengue infections that can even cause the death of the infected person.